Julius W Jaeger, Annette Brandt, Wenfang Gui, Timur Yergaliyev, Angélica Hernández-Arriaga, Mukil Marutha Muthu, Karolina Edlund, Ahmed Elashy, Antonio Molinaro, Diana Möckel, Jan Sarges, Emina Halibasic, Michael Trauner, Florian Kahles, Ulrike Rolle-Kampczyk, Jan Hengstler, Carolin Victoria Schneider, Twan Lammers, Hanns-Ulrich Marschall, Martin von Bergen, Amélia Camarinha-Silva, Ina Bergheim, Christian Trautwein, Kai Markus Schneider
BACKGROUND & AIMS: Changes in gut microbiota in metabolic dysfunction-associated steatotic liver disease (MASLD) are important drivers of disease progression towards fibrosis. Therefore, reversing microbial alterations could ameliorate MASLD progression. Oat beta-glucan, a non-digestible polysaccharide, has shown promising therapeutic effects on hyperlipidemia associated with MASLD, but its impact on gut microbiota and most importantly MASLD-related fibrosis remains unknown. METHODS: We performed detailed metabolic phenotyping, including assessments of body composition, glucose tolerance, and lipid metabolism, as well as comprehensive characterization of the gut-liver axis in a western-style diet (WSD)-induced model of MASLD and assessed the effect of a beta-glucan intervention on early and advanced liver disease...
March 2024: JHEP reports: innovation in hepatology